Literature DB >> 29551465

The possible role of maintenance treatment for primary central nervous system lymphoma.

Osnat Bairey1, Tali Siegal2.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. The elderly patients are also susceptible to the accelerated and detrimental cognitive side effects of whole-brain irradiation which is an alternative consolidation to high-dose chemotherapy. Maintenance therapy has been shown to be a promising strategy to prolong remission time in other hematopoietic malignancies. Herein, we discuss the place of maintenance treatment in PCNSL in view of perspective obtained from hematological malignancies and non-Hodgkin's lymphoma.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CNS lymphoma; Immune modulating therapy; Maintenance treatment; Metronomic therapy; Primary CNS lymphoma; Targeted therapy

Mesh:

Year:  2018        PMID: 29551465     DOI: 10.1016/j.blre.2018.03.003

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  6 in total

1.  Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.

Authors:  Tadashi Okamura; Hiroki Hosoi; Takeshi Matsufusa; Yuina Akagi; Ryuta Iwamoto; Hideki Kosako; Shogo Murata; Toshiki Mushino; Shin-Ichi Murata; Takashi Sonoki
Journal:  Ann Hematol       Date:  2022-01-27       Impact factor: 3.673

Review 2.  Central Nervous System Lymphoma: Novel Therapies.

Authors:  Shannon P Fortin Ensign; Diamone Gathers; Julia Erin Wiedmeier; Maciej M Mrugala
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

3.  Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.

Authors:  Jing-Jing Wu; Wen-Hua Wang; Meng Dong; Shan-Shan Ma; Xu-Dong Zhang; Li-Nan Zhu; Song-Tao Niu; Meng-Jie Ding; Jie-Ming Zhang; Lei Zhang; Xin Li; Ling Li; Zhen-Chang Sun; Xin-Hua Wang; Xiao-Rui Fu; Zhao-Ming Li; Yu Chang; Fei-Fei Nan; Jia-Qin Yan; Hui Yu; Xiao-Long Wu; Zhi-Yuan Zhou; Ming-Zhi Zhang
Journal:  Invest New Drugs       Date:  2022-02-09       Impact factor: 3.651

Review 4.  Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity.

Authors:  Kun-Wei Song; Tracy Batchelor
Journal:  Curr Oncol Rep       Date:  2021-09-15       Impact factor: 5.075

5.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

6.  Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort.

Authors:  Christian Iorio-Morin; Gérald Gahide; Christophe Morin; Davy Vanderweyen; Marie-André Roy; Isabelle St-Pierre; Karine Massicotte-Tisluck; David Fortin
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.